Navigation Links
ImQuest Presentations at Keystone Symposium Focus on Advancements in Their Therapeutic and Microbicide Development Programs
Date:3/25/2009

FREDERICK, Md., March 25 /PRNewswire/ -- ImQuest Life Sciences presented their latest biological results supporting the continued development of their small molecule pyrimidinedione inhibitors of HIV-1 at the Prevention of meeting being held in Keystone, Colorado. The presentations highlighted new data supporting the selection of lead second generation therapeutic agents with an increased barrier to the selection of drug resistant virus strains in treated patients, as well as preclinical studies supporting the development of the pyrimidinedione IQP-0528 as a topical microbicide candidate for human clinical trials. The pyrimidinediones are highly potent inhibitors of HIV, exhibiting a dual mechanism of action which includes targeting virus entry and reverse transcription, a highly positive safety profile, and enhanced sensitivity against multi-drug resistant viruses isolated from patients. ImQuest recently submitted an Investigational New Drug Application to the FDA to initiate Phase 1 human clinical trials with the pyrimidinedione IQP-0410.

Robert W. Buckheit, Jr., Ph.D. (Executive Vice President and Chief Scientific Officer) presented the results of studies which demonstrate the ability of various analogs of IQP-0410 to more effectively suppress the replication of viruses which are resistant to the action of other NNRTIs used in the clinic. ImQuest, in collaboration with their drug development partner Samjin Pharmaceutical Co. Ltd of Seoul, Korea, have recently engaged in an effort to develop more active pyrimidinediones possessing this higher genetic barrier to resistance. Karen M. Watson, M.S. (Director, Topical Microbicide Research & Development) reported on results of preclinical efficacy evaluations of a series of pyrimidinediones, resulting in the selection of IQP-0528 as ImQuest's lead compound to prevent the sexual transmission of HIV worldwide. The studies included ImQuest co-authors Tracy Hartman, M.S., Lu Yang, M.D. and Chr
'/>"/>

SOURCE ImQuest Life Sciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. ImQuest Presents New Anti-HIV Drug and Topical Microbicide Development Results on Lead Pyrimidinedione Products IQP-0410 and IQP-0528
2. SimQuest Awarded Phase 2 Contract from Office of the Secretary of Defense to Develop Pandemic Influenza Training Program
3. Accuray to Webcast Senior Management Presentations at Analyst Day Event
4. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference
5. Forest Laboratories and Cypress Bioscience to Host Webcast to Discuss Clinical Data Presentations for Milnacipran
6. Cell Therapeutics, Inc. (CTI) CIBC and Rodman & Renshaw Healthcare Conference Presentations to be Webcast
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
8. Inexpensive Online Pain Education Program for Physicians as Effective as Live Presentations by National Experts
9. Derma Sciences Announces Several Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming APWCA Conference
10. Uroplasty, Inc. Reports Presentations of Urgent(R) PC Studies at the 2008 Society of Urologic Nurses and Associates Annual Symposium
11. Trubion Announces Presentations at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/2/2015)... Francisco, California (PRWEB) April 02, 2015 ... science campaign on March 19th, 2015, two years after ... the human microbiome. The biotech startup sparked the era ... engaged with the public to provide easily accessible information ... DNA sequencing technology. In less than two weeks from ...
(Date:4/2/2015)... Miami, FL (PRWEB) April 02, 2015 ... Track and Field gets its start! Runners have been ... are ready to start racing. Zensah®, a premium compression ... to help ensure the athletes are benefiting from ... , Zensah® is a Miami-based company, committed to using ...
(Date:4/2/2015)... On Wednesday, April 15, Registrar Corp will present ... where food industry professionals gather to network and assess ... Registrar Corp Vice President David Lennarz will go over ... food and beverages to the United States and inform ... inspection. The seminar will begin at 13:30 at Open ...
(Date:4/2/2015)... Grab your favorite latte or cup of tea ... trends with the all-new, half-hour debut of the lifestyle talk ... AM ET/PT, 6:00 AM CT, and 5:00 AM MT on ... product strategist Forbes Riley, Forbes Living TV brings ... entrepreneurs, inventors, and innovators whose creations are driving the latest ...
(Date:4/2/2015)... (PRWEB) April 02, 2015 Veale Outdoor ... now two digital billboards to its name, announces its ... in the Dixon/Sacramento area. Similar to the first ... in Rohnert Park, California, the addition means, in total, ... the much sought after tourist population traveling through the ...
Breaking Medicine News(10 mins):Health News:uBiome’s Dental Campaign to Give Portion of Proceeds to Charitable Dental Organization 2Health News:uBiome’s Dental Campaign to Give Portion of Proceeds to Charitable Dental Organization 3Health News:uBiome’s Dental Campaign to Give Portion of Proceeds to Charitable Dental Organization 4Health News:Zensah® Partners With Austin Track Club 2Health News:Zensah® Partners With Austin Track Club 3Health News:Registrar Corp to Present FDA Regulation Seminar at Worldfood Warsaw 2Health News:Registrar Corp to Present FDA Regulation Seminar at Worldfood Warsaw 3Health News:Forbes Living Showcases Trendsetters on Discovery Channel Transponder 2Health News:Forbes Living Showcases Trendsetters on Discovery Channel Transponder 3Health News:Veale Outdoor Advertising State of the Art Digital Billboards Reach 12 Million in SF Bay Area 2
... DURHAM, N.C. Wireless, personal computers used by cancer patients ... further cancer research, according to a study led by researchers ... see if patient-reported data generated at the point of care ... care and research," said Amy Abernethy, M.D., an oncologist at ...
... of individuals at risk for gastrointestinal cancers, researchers ... many people misjudge their actual degree of cancer ... support. Strategies for accurately assessing cancer risk are ... resources to prevent cancer in as many individuals ...
... for deadly cancer, , , THURSDAY, May 14 (HealthDay News) ... immune-based treatment boosted by 20 percent the overall survival ... , The findings are to be presented at the ... later this month in Florida. , The trial involved ...
... among breast cancer patients , , THURSDAY, May 14 (HealthDay ... ginger that many grandmothers are already familiar with, and ... undergoing chemotherapy. , "Ginger at a daily dose of ... nausea on the first day of chemotherapy, and reduced ...
... May 14 Thoratec Corporation (Nasdaq: THOR ), ... to save, support and restore failing hearts, said today ... JMP Securities Research Conference on Monday, May 18.David. V. ... provide an update on the company, beginning at 2 ...
... BIRMINGHAM, Ala., May 14 BioCryst Pharmaceuticals ... from a Phase 2 study of forodesine, the Company,s ... (CTCL). The data will be presented at the ... Oncology (ASCO) being held in Orlando, Florida from May ...
Cached Medicine News:Health News:Patient-centered approach to capturing data from cancer patients improves care and research 2Health News:Perceived cancer risks may not reflect actual risks or prevention needs 2Health News:Immune Therapy May Aid Kids With Neuroblastoma 2Health News:Ginger Eases Nausea From Chemo 2Health News:BioCryst Pharmaceuticals Announces Presentation of Forodesine Data at the 45th Annual Meeting of the American Society of Clinical Oncology 2Health News:BioCryst Pharmaceuticals Announces Presentation of Forodesine Data at the 45th Annual Meeting of the American Society of Clinical Oncology 3Health News:BioCryst Pharmaceuticals Announces Presentation of Forodesine Data at the 45th Annual Meeting of the American Society of Clinical Oncology 4
(Date:4/2/2015)...  Men diagnosed with prostate cancer may struggle with ... sexual function. Often, many treatment conversations start with ... "Knowing what to expect is a large part of ... work very closely with men and their partners before, ... likely to occur," said Dr. David Samadi , ...
(Date:4/1/2015)... night, several months after a motorcycle crash paralyzed him from the ... Roosevelt "R.J." Anderson Jr. had a dream: he could walk again. ... friend using an exoskeleton device to walk at the Rehabilitation Institute ... receiving treatment. He decided then and there that he would one ... first person in Chicago to receive a ...
(Date:4/1/2015)... April 1, 2015  Diplomat Pharmacy, Inc. (NYSE: ... of BioRx, LLC, a highly specialized pharmacy and infusion ... and rare, chronic diseases based in Cincinnati, ... the combined resources and capabilities will make Diplomat one ... Diplomat and BioRx are dedicated to personalized medication therapies ...
Breaking Medicine Technology:Sex After Prostate Cancer Made Possible by World-Renowned Robotic Prostate Cancer Surgeon, Dr. David Samadi, using SMART Technique 2Sex After Prostate Cancer Made Possible by World-Renowned Robotic Prostate Cancer Surgeon, Dr. David Samadi, using SMART Technique 3Dream Comes True: Paralyzed Veteran Walks Again, Thanks to Robotic Exoskeleton System at Rehabilitation Institute of Chicago 2Dream Comes True: Paralyzed Veteran Walks Again, Thanks to Robotic Exoskeleton System at Rehabilitation Institute of Chicago 3Diplomat Completes Acquisition of BioRx 2Diplomat Completes Acquisition of BioRx 3Diplomat Completes Acquisition of BioRx 4
... Calif., Sept. 29 Zeltiq Aesthetics, a science-based medical device ... reduction of unwanted fat tissue, has announced the appointment of ... Nye succeeds Mitch Levinson, the founder of Zeltiq Aesthetics, who ... Officer and a member of the Board of Directors since ...
... N.Y., Sept. 29 Misonix, Inc. (Nasdaq: MSON ... technology, which in Europe is used for the ablation ... today announced plans to release fourth quarter and fiscal ... afternoon, October 1, 2009. Michael A. McManus, President ...
Cached Medicine Technology:Zeltiq Aesthetics Names Gordie Nye to Serve as New CEO 2Zeltiq Aesthetics Names Gordie Nye to Serve as New CEO 3Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: